| Execution period | Lifetime |
|---|
BSE filing, NSE: JAYKAY. Summary written from the filing by ALFA Finder's alert engine.
Jaykay Enterprises Ltd: key numbers
- Share price
- ₹201.22
- Market cap
- ₹2,829 Cr
- Revenue (annual)
- ₹239.7 Cr
- Net profit (annual)
- ₹232.5 Cr
- P/E (TTM)
- 14.2×Sector 52.0×
- Promoter holding
- 66.00%+0.81% QoQ
- FII holding
- 0.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jaykay Enterprises Ltd
All →Jaykay Enterprises Other Announcement
Jaykay Enterprises Ltd has submitted its quarterly shareholding pattern report under Regulation 31(1)(b) for the period ended September 30, 2026.
Jaykay Enterprises Employee Stock Options
Jaykay Enterprises granted 13,000 stock options at Rs. 215.01 per option under its 2025 ESOP scheme. Vesting spans three years with a two-year exercise window.
Jaykay Enterprises Debt & Borrowing: ₹100 Cr
Jaykay Enterprises Limited has executed a loan agreement to provide an inter-corporate deposit of up to ₹100 Crore to its subsidiary, JK Defence & Aerospace Limited.
- Value
- ₹100.0 Cr
Jaykay Enterprises Acquisition Worth ₹25 Cr
Jaykay Enterprises acquired 25 lakh preference shares in its wholly-owned subsidiary, JK Defence & Aerospace Limited, for ₹25 Crore. This transaction involves a cash capital infusion.
- Value
- ₹25.00 Cr
Jaykay Enterprises Acquisition Worth ₹2 Cr
Jaykay Enterprises acquired additional preference shares in its wholly-owned subsidiary, JK Digital & Advance Systems, for Rs. 2 Crore.
- Value
- ₹2.00 Cr
Jaykay Enterprises Management Change
Jaykay Enterprises Limited announced the re-appointment of Mr. Abhishek Singhania and Mr. Partho Pratim Kar as Executive Directors. The appointments are for terms of 24 to 36 months.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.